

Product datasheet

Anti-Bag3 antibody ab5898

1 References

Overview

Product name	Anti-Bag3 antibody
Description	Goat polyclonal to Bag3
Host species	Goat
Tested applications	Suitable for: IP, WB
Species reactivity	Reacts with: Human
Immunogen	Synthetic peptide: SSMTDTPGNPAAP, corresponding to C terminal amino acids 563-575 of Human Bag3. Run BLAST with ExPASy Run BLAST with NCBI
Positive control	Human skeletal muscle lysates.
General notes	GenBank Accession Number – NP_004272

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer	Preservative: 0.02% Sodium Azide Constituents: 0.5% BSA, Tris buffered saline, pH 7.3
Purity	Immunogen affinity purified
Purification notes	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Clonality	Polyclonal
Isotype	IgG

Applications

Our [Abpromise guarantee](#) covers the use of **ab5898** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
IP		Use at an assay dependent concentration. PubMed: 23341456
WB		Use a concentration of 0.1 - 0.3 µg/ml. Can be blocked with Human Bag3 peptide (ab23111) . Approx 85kDa band observed in Human skeletal muscle lysates (calculated MW of 61.6kDa according to NP_004272.2). The observed molecular weight corresponds to earlier findings in literature with different antibodies (Iwasaki et al, Cancer Res. 2007 Nov 1;67(21):10252-9. PMID: 17974966).

Target

Function	Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity.
Involvement in disease	Defects in BAG3 are the cause of myopathy myofibrillar BAG3-related (MFM-BAG3) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients. At ultrastructural level, muscle fibers display structural alterations consisting of replacement of the normal myofibrillar markings by small, dense granules, or larger hyaline masses, or amorphous material.
Sequence similarities	Contains 1 BAG domain. Contains 2 WW domains.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <http://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors